OpGen’s Infectious Disease Portfolio Highlighted at IDWeek 2016
October 26 2016 - 7:00AM
OpGen, Inc. (NASDAQ:OPGN) today announced that its infectious
disease portfolio will be featured in one oral presentation and 5
poster sessions at IDWeek 2016, which takes place from October
26-30 in New Orleans, LA.
The oral presentation, given by Jacqueline Reuben, Senior
Infectious Disease Epidemiologist, District of Columbia Department
of Health, will illustrate OpGen’s Acuitas Lighthouse® MDRO
Management System capabilities in a regional prevalence study,
called HARP-DC, of multi-drug resistant organisms (MDROs) in
Washington, D.C. healthcare facilities. Additional data presented
will highlight:
- The company’s expertise in informatics and genomic analysis to
support the need for preventative frameworks within health
facilities.
- OpGen’s Acuitas® MDRO Gene Test in examining the
potential of fecal microbiota transplantation (FMT) to reverse
dysbiosis and eliminate colonization with antibiotic-resistant
organisms.
“The data presented at IDWeek demonstrate OpGen’s commitment to
arming hospitals and health systems with the next generation of
genomic and informatics solutions to resolve often underestimated
infectious disease threats,” said Evan Jones, CEO and Chairman of
OpGen. “With these data, we are demonstrating our capabilities to
assist in the fight against antimicrobial resistance and the
importance of implementing effective preventative frameworks across
all health systems.”
The scheduled times and titles of the poster sessions and
presentation are as follows:
Thursday, October 27 from 12:30 PM – 2:00 PM
CDT
- Healthcare Antibiotic Resistance Prevalence – DC (HARP - DC) –
Measuring the Prevalence of vanA genes in Healthcare Facilities
(HCFs) in Washington, D.C. (Poster #312 in Poster Hall) presented
by Jacqueline Reuben, MHS, District of Columbia Department of
Health
- Measuring the Prevalence of Multidrug Resistant Acinetobacter
(MDRA) Using OXA 23 and OXA 51 Gene Identification in Healthcare
Facilities (HCFs) in Washington, D.C. (Poster #323 in Poster Hall)
presented by Jacqueline Reuben, MHS, District of Columbia
Department of Health
- Assessing Carbapenemase Resistant Enterobacteriaceae (CRE)
Prevalence Using a Combined Antibiotic Resistance Gene Assay and
Surveillance Cultures in Hospitalized Patients (Poster #344 in
Poster Hall) presented by Rebecca Kumar, M.D., Georgetown
University
- Prevalence of Multi-Drug Resistant Organism (MDRO) Using an
Antibiotic Resistant Gene Assay at a Tertiary Care Center (Poster
#325 in Poster Hall) presented by Joseph Timpone, M.D., Department
of Medicine, Georgetown University
Saturday, October 29 from 12:30 PM – 2:00 PM
CDT
- Clearance of Vancomycin-Resistant Enterococcus Colonization
with Fecal Microbiota Transplantation among Patients with Recurrent
Clostridium Difficile Infection (Poster #2119 in Poster Hall)
presented by Lindsay Eysenbach, AB, Nonprofit Management Fellow at
OpenBiome
Saturday, October 29 at 2:00 PM CDT – Oral
Presentation
- Healthcare Antibiotic Resistance Prevalence – DC (HARP - DC)-
Measuring the Prevalence of Carbapenem Resistant Enterobacteriaceae
in Healthcare Facilities (HCF) in Washington, D.C. (Room 388-390)
presented by Jacqueline Reuben, MHS, District of Columbia
Department of Health
In addition to these data presentations, initial data from the
Intermountain Healthcare retrospective study evaluating the shift
in epidemiology in drug resistant organisms over an eight-year
period will be presented on Thursday, October 27 at 12:30 p.m. CDT
by Dr. Bert Lopansri, lead author of the study at Intermountain
Medical Center. He will also host a discussion of the study
and its results at the Learning Lounge. The discussion is titled,
“Antibiotic resistant bacteria in our Integrated Healthcare
Network: are new diagnostic tests needed?” and will take place on
Saturday, October 29, 2016 from 1:15 p.m. to 1:45 p.m. CDT at booth
#1300.
About OpGenOpGen, Inc. is harnessing the power
of informatics and genomic analysis to provide complete solutions
for patient, hospital and network-wide infection prevention and
treatment. Learn more at www.opgen.com and follow OpGen on Twitter
and LinkedIn.
Company Contact:
Michael Farmer
Director, Marketing
(240) 813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
Investor and Media Contact:
MacDougall Biomedical Communications
Cammy Duong
781-235-3060
cduong@macbiocom.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024